NGeneBio Co., Ltd. (KOSDAQ:354200)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,704.00
+3.00 (0.18%)
At close: Dec 5, 2025
-29.15%
Market Cap 42.66B
Revenue (ttm) 9.98B
Net Income (ttm) -12.96B
Shares Out 25.04M
EPS (ttm) -824.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,359
Average Volume 55,882
Open 1,698.00
Previous Close 1,701.00
Day's Range 1,694.00 - 1,716.00
52-Week Range 1,330.00 - 2,735.00
Beta 1.06
RSI 57.85
Earnings Date Mar 20, 2026

About NGeneBio

NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myeloproliferative neoplasm, multiple myeloma, and lymphoma; SOLIDaccuTest, a genetic variants screening for solid tumors; HLAaccuTest, an in vitro diagnostic ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 354200
Full Company Profile

Financial Performance

In 2024, NGeneBio's revenue was 5.69 billion, an increase of 30.80% compared to the previous year's 4.35 billion. Losses were -12.63 billion, -1.11% less than in 2023.

Financial Statements

News

There is no news available yet.